VEGFR1/2/3 drugs for Renal Cell Carcinoma
2 tracked VEGFR1/2/3 drugs in the Renal Cell Carcinoma race. The class explanation lives on the VEGFR1/2/3 page; the full indication pipeline across every mechanism is on the Renal Cell Carcinoma page.
1 approved / phase 41 Phase 3
Head-to-head evidence: Axitinib vs Fruquintinib